On September 15, 2021, Qi Huili, Deputy Director of the Shaanxi Food and Drug Administration, Qu Jianpeng, Director of the Drug Circulation Supervision Department of the Shaanxi Drug Administration and other leaders visited Shaanxi Tiandren and Pharmaceutical, a subsidiary of our Group, to inspect and guide the work. Mr. Yang Cheng, chairman of Huachuang Synthesis Group, warmly received and accompanied me throughout the whole process.
       Yang Cheng, chairman of Huachang Synthesis Group, reported the work to the leadership of the Food and Drug Administration.
      Accompanied by the chairman, the leaders of the FDA visited the office building, research and development laboratory, third-party testing laboratory, and drug production workshop of our company, and focused on the exclusive products of our company.

Subsequently, at the panel meeting held, Yang Cheng, chairman of Huachuang Synthesis Group, and Huang Hong, deputy general manager of Huachuang Synthesis Group's clinical Department, reported to the leadership of the FDA from the aspects of the company's development history, industrial layout, core business model, etc. Huang Hong supplemented the company's values of "rigorous, pragmatic, innovative and progressive" and its future planning in key strategic directions such as precision medicine and medical service platform. Since its establishment in 2009, Huachuang Synthetic Pharmaceutical Co., Ltd. is a high-tech enterprise committed to drug research and development and technology transfer. The company was listed on the New Third Board in March 2015, and its research and development scope is mainly the development of innovative drugs and high-quality generic drugs, and independent research and development of new drugs with stronger efficacy and higher safety. The development direction of innovative drugs is mainly small molecule innovative drugs. At present, the company has successfully transformed into an integrated industrial cluster of research, production and marketing combining Chinese and Western medicine.

At the meeting, the participants had a warm interactive exchange and discussion on hot issues such as our company's business model, production capacity, precision medicine and new drug research.
      Comrade Qi Huili praised our product research and development ability and quality management. In particular, we highly affirm the achievements made by our company in recent years and the contributions made to the development of the Chinese medicine industry. At the same time, we are encouraged to keep up with the pace of development of The Times, deeply study national policies, actively promote industrial upgrading, jointly cope with the challenges of digitalization and specialization of the industry, and actively explore in the fields of Chinese medicine preparations and real world research. At the same time, we hope that while developing enterprises, we can communicate with the government and associations on policies and systems in a timely manner, and jointly help the high-quality development of healthy China.